Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy-Reference-Cited by-同舟云学术

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

Published:2015-11 Issue:11 Volume:10 Page:1601-1607
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Al-Halabi Hani,Sayegh Karl,Digamurthy Subba R.,Niemierko Andrzej,Piotrowska Zofia,Willers Henning,Sequist Lecia V.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story;Sequist;Ann Rev Med,2008

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations;Sequist;J Clin Oncol,2008

4. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients;Sequist;J Thorac Oncol,2008

5. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study;Douillard;Br J Cancer,2001

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs;BMC Cancer;2024-08-26

2. Treatment sequences in EGFR mutant advanced NSCLC;Lung Cancer;2024-08

3. Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease;Cancer Discovery;2024-06-03

4. Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach;Exploration of Targeted Anti-tumor Therapy;2024-05-17

5. Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study;Cancer Medicine;2024-04